DR. CAMPOS CONTRIBUTES TO STUDY IN TARGETED ONCOLOGY JOURNAL


Dr. Luis T. Campos recently contributed in a study in the Targeted Oncology journal. The study was titled: "Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer."

The article is currently hosted on Springer International Publishing and can be view here: http://link.springer.com/article/10.1007/s11523-015-0394-5?email.event.1.SEM.ArticleAuthorContributingOnlineFirst


Recent Posts
Archive